In a recent interview with CGTN anchor Zheng Junfeng, AstraZeneca CEO Pascal Soriot shed light on the company’s comprehensive strategy within the pharmaceutical industry of the Chinese mainland. AstraZeneca is not only focusing on the domestic market but is also positioning the Chinese mainland as a key base for global manufacturing and innovation.
The company has made significant investments in major cities like Wuxi and Qingdao, underscoring its commitment to expanding its footprint and enhancing research and development capabilities. These strategic moves are aimed at fostering advancements in global health and contributing to the economic growth of the region.
With a strong emphasis on R&D, AstraZeneca is poised to drive innovation in the pharmaceutical sector, ensuring that cutting-edge treatments and solutions reach patients worldwide. This dedication to growth and development in the Chinese mainland highlights AstraZeneca’s role as a pivotal player in the global healthcare landscape.
Reference(s):
AstraZeneca in China: Innovation, Investment, and Commitment
cgtn.com
